Patients with AD and diabetes have higher levels of interleukin 6 (IL-6) in cerebrospinal fluid (CSF), more pronounced tau hyperphosphorylation, increased accumulation of beta-amyloid and more ischemic lesions in the central nervous system (CNS) in comparison with patients with AD and normal glucose metabolism [11]. Here, MAPT is linked to Alzheimer disease.